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Abstract
Antibody-drug conjugates (ADCs) of defined structure hold great promise for cancer therapies, but 
further advances are constrained by the complex structures of full-sized antibodies. Camelid-
derived single domain antibody fragments (VHHs or nanobodies) offer possible solutions to this 
challenge by providing expedited target screening/validation through shuttling between imaging 
and therapy. Here, we used a nanobody (VHH7) specific for murine MHC-II and rendered sortase-
ready for introduction of oligoglycine-modified cytotoxic payloads or NIR fluorophores. The 
VHH7 conjugates outcompeted commercial mAbs for internalization and exhibited high 
specificity and cytotoxicity against the A20 murine B-cell lymphoma. Non-invasive NIR imaging 
with a VHH7-fluorophore conjugate showed rapid tumor targeting on both localized and 
metastatic lymphoma models. Subsequent treatment with the nanobody-drug conjugate efficiently 
controlled tumor growth and metastasis without obvious systemic toxicity.
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B-cell lymphoma is the most common type of non-Hodgkin's lymphoma (NHL). The 
American Cancer Society estimates that in 2015, ~70,000 new cases of NHL will be 
diagnosed in the United States, with mortality around ~20,000 patients. Antibodies against a 
variety of cellular receptors or antigens on B cells such as CD20,[1] surface 
immunoglobulins,[2] Class II major histocompatibility complex antigens (MHC-II),[3] 
CD80/CD86,[4] and CD40[5] have shown efficacy in treating B cell malignancies. The 
therapeutic mAb and ADC target CD20 (Rituximab) and CD30 (Brentuximab vedotin) 
represent a significant advance in the management of B cell malignancies.
Without exception, ADCs in the clinic so far rely on full-sized mAbs and on a rather limited 
range of conjugation methods, at times resulting in heterogeneous mixtures.[6] Accurate 
prediction of the drug:antibody ratio (DAR), crucial to the pharmaceutical properties of 
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ADCs and the translation of the manufacturing process from one antibody to another,[7] 
requires sophisticated mass spectroscopic methods and time-consuming empirical 
optimizations.[8] Recent efforts in making homogeneous ADCs[9] involve direct genetic 
approaches to install reactive cysteine residues,[10] unnatural amino acids,[11, 12] 
formylglycine-generating enzyme[13], or sortase[14] recognition motifs, or indirect 
glyco-[15, 16] or metabolic[17] engineering of the conserved N-glycan of the IgG Fc-domain. 
The structural complexity and post-translational modifications of mAbs complicate the 
straightforward expression and preparation of functionalized mAbs. To simplify mAbs while 
retaining essential functions, antibody fragments (scFv and Fab) and their engineered 
variants (diabodies, triabodies, minibodies) are the smaller format of choice.[18] Similar 
conjugation methods are generally transferable to antibody fragments. Their conjugates with 
radioactive tracers,[19, 20] nanomaterials,[21, 22] gene products,[23] immunomodulators,[24] 
cytotoxic reagents,[25, 26] or a combination[27] have demonstrated great maneuverability in 
therapeutic and diagnostic applications.
The discovery of unique heavy chain-only antibodies (HcAbs) in the family of 
Camelidae,[28] showed that their variable domains (VHHs), the smallest naturally derived 
antigen-binding fragment (~15KDa), retain antigen binding capacity when expressed 
recombinantly. The small size greatly benefits rapid circulatory clearance and reduces 
background in an non-invasive imaging setting.[19, 29] Their single domain nature allows 
convenient phagemid-based screening. The inherent absence of a hydrophobic surface that is 
usually present between VH and VL improves VHH solubility providing high yield (50 
mg/L) in an E. coli expression system. No major framework rearrangements of VHHs have 
been observed, while the CDR3 domain is primarily involved in antigen binding and 
protrudes from the remaining binding surface, with the C-terminus extending in the opposite 
direction.[30] This justifies the installation of a C-terminal pentapeptide sortase recognition 
motif LPXTG, which, in turn, provides near limitless possibilities for site-specific 
modifications without compromising binding properties of the modified VHHs.[31–33] 
Collectively, nanobody-drug conjugates are desirable targets to develop the next generation 
of ADCs.[34]
We identified a VHH (VHH7) that binds murine class II major histocompatibility complex 
(MHC-II) molecules with low nM affinity. MHC-II is expressed on professional antigen 
presenting cells such as dendritic cells, B-cells, and macrophages. Compared to other B-cell 
markers like CD20, MHC-II is highly expressed on the B-cell surface (8*104 /cell for MHC-
II v.s. 9*103 /cell for CD20) [35, 36] and can be upregulated by antibody (rituximab) or 
immunostimulants such as CpG,[37] or IFN-γ[38]. Single agent therapy using two courses of 
Rituximab allows the outgrowth of CD20 loss variants in NHL patients, indicating a need 
for complimentary targets.[39]
We report here the preparation of a structurally defined nanobody-drug conjugate (VHH7-
DM1) using sortase-mediated site-specific protein engineering, its pharmacokinetics and in 
vivo targeting as corroborated by non-invasive optical imaging. We show a therapeutic 
benefit of this conjugate by treating both a localized and a disseminated murine B-cell 
lymphoma, using the A20 cell line as a model.
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To prepare a structurally defined VHH7-drug conjugate, we chose a thio-containing 
Maytansine derivative, Mertansine (DM1), as our cytotoxic payload. DM1 is a potent 
inhibitor of microtubule polymerization that has no useful therapeutic window when used as 
a single agent, but has been used to create ADCs.[40] Studies of Trastuzumab-emtansine 
(Kadcyla) showed that conjugation of DM1 to mAbs through a non-cleavable succinimidyl 
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker, followed by the 
proteolytic degradation of this construct in endosomes/lysosomes, gave favorable clinical 
results in a phase III trial when compared to a cleavable disulfide linker.[41] Accordingly, we 
explored the sequential thiol-Michael ligation of a bis(maleimido)ethane (BMOE) linker[42] 
with the free mercapto group of hydrophilic peptide 1 and DM1 (Figure 1a). Using 5 
equivalents of BMOE, peptide 1 is labeled monovalently and quantitatively after 16 h at 
room temperature in DMF. Excess BMOE was precipitated by the addition of water and the 
reaction mixture was purified by RP-HPLC, lyophilized, then converted to 2 after reacting 
with 2 equivalents of DM1 to give 80% conversion after 16 h, based on the integration of the 
HPLC trace. The sortase reaction between VHH7 and 2 was carried out following 
established protocols[43, 44] in which unreacted VHH7 and sortase were removed by 
incubation with Ni-NTA agarose beads, leaving product 3 and excess nucleophile 2, which 
were easily separated by size exclusion chromatography (SEC) to obtain the desired product 
3 . Identity of the conjugate was confirmed by LC-MS (Figure 1b) and when analyzed by 
SDS-PAGE the product yielded a single band (Figure 1c).
We also modified VHHs with a NIR dye, Alexa Fluor 647 (AF647) through sortagging. 
Binding of VHH7 to MHC-II positive A20 cells was measured at various concentrations of 
VHH7-AF647 and assessed by flow cytometry, showing half maximal binding (EC50) at 2.1 
nM (Figure 2a). Kinetics of VHH7 internalization were determined by incubation of A20 
cells with VHH7-AF647, a genetic dimer of VHH7 labelled with AF647, a commercial anti-
I-A/E IgGκ-AF488, and an irrelevant anti-human integrin VHH (2B7), followed by surface 
staining with anti-IgG-AF591 and analysis by confocal microscopy (Figure S3). Monovalent 
VHH7-AF647 was internalized within 1 h, while the internalization of the commercial anti-
I-A/E reagent was observed only after overnight incubation. We tested the internalization of 
a bivalent format of VHH7, which is a tandem N to C arrangement of two VHH7 units with 
a single C-terminal AF647. A similar rate of internalization was observed for the dimer 
when applied at the same concentration. We performed a competition study by co-incubation 
of A20 cells with VHH7-AF647 and anti-I-A/E IgGκ-AF488, and saw that VHH7 was 
internalized rapidly and appeared in vesicular structures within 5 min, leaving the 
commercial anti-I-A/E reagent visible as a rim stain (Figure 2b). The rapid internalization of 
VHH7 upon binding to MHC-II suggested its use for targeted drug delivery. In contrast, 
CD20 is not internalized as rapidly, making it a better mediator of ADCC.[45] An anti-EGFR 
nanobody also showed slow internalization.[46]. The choice of target as it relates to its 
internalization is thus an important parameter in the design of VHH-drug conjugates.
We studied the in vitro cytotoxicity of the VHH7-DM1 conjugate against the murine 
lymphoma A20, and MHC-II negative cell lines such as HeLa and HEK293 (Figure 2c, S2). 
Cells (4×104 per well in a 96 well plate) were exposed to VHH7-DM1 or to unconjugated 
DM1 at increasing concentrations. The VHH-DM1 fusion effectively killed A20 cells with 
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an IC50 = 36 nM; however, HeLa and HEK293 required ~500 nM (Figure S2), 
demonstrating the selective action of the VHH-DM1 fusion. The unconjugated drug shows 
similar cytotoxicity for all three cell lines.
We confirmed systemic targeting against A20 lymphoma in both localized and metastatic 
models by non-invasive optical imaging. We detected the subcutaneous tumor after i.v. 
injection of VHH7-AF647 as monitored by IVIS (Figure 3a,b). Injection of an irrelevant 
nanobody-AF647 conjugate (Enh-AF647) into an A20 -bearing mouse, or injection of VHH-
AF647 into a MHC-II KO mouse resulted in rapid clearance without signs of non-specific 
binding at the tumor site. The average radiant efficiency of the tumor and the S/N ratio at 
different time points (Figure S6) suggested that in vivo targeting reached a maximum at 30 
min and persisted over the next 96 h. The signal from the kidney reached its maximum 
within 5 h and then progressively decreased, consistent with kidneys being the major 
clearance pathway for VHHs.[47] Targeting at the cellular level was also confirmed when 
tumors were removed 2 h p.i. of VHH7-AF647 compared to Enh-AF647, frozen, sectioned, 
and mounted for confocal microscopy (Figure S4). Vesicular structures were observed for 
samples from VHH7-AF647 injected mice, while no signal was detected for Enh-AF647.
Lung, liver, spleen and lymph nodes are all possible sites of invasion in the case of 
disseminated lymphoma. We observed strong signals from the lungs and liver by NIR 
imaging (Figure 3c, d), whereas signals from healthy Balb/c mainly emanated from the GI 
tract and bladder. To confirm targeting of VHH7 to metastatic foci, both healthy and tumor-
bearing mice were injected with 40 µg VHH7-AF647, dissected, followed by comparison of 
fluorescent signals from lung, liver and spleen (Figure 3e). The presence of lymphoma in 
these organs was first confirmed cytologically. Metastasic foci were found in liver, with 
splenomegaly as a consequence of tumor infiltration. NIR-imaging was consistent with the 
cytological observations: all tumor-bearing organs showed strong fluorescent signals. The 
fluorescent signal persists even after 24 h, owing to retention of VHH7 at the tumor site, 
with delayed clearance compared to healthy mice (Figure 3f,g). A meaningful comparison of 
the biodistribution of VHH7 and full-sized αI-A/E would require a full-sized Ab of the 
identical specificity and labelled to the same intensity, a preparation that we currently lack. 
VHH7 is monovalently labelled, while the full-sized α-I-A/E has 8~10 fluorophores per 
molecule. When VHH7 and full-sized α-I-A/E were injected at the same fluorescent dose, a 
stronger signal was seen for VHH7 at the tumor site (Figure 3h). Injection of similar molar 
quantities of VHH7 and full-sized α-I-A/E showed increased staining of VHH7 for spleen 
and inguinal lymph nodes comparing to α-I-A/E (Figure S8).
Finally, the VHH7-DM1 conjugate was subjected to tests in vivo to treat the highly invasive 
A20 lymphoma, known to target spleen, liver and lymph nodes. The A20 tumors are 
radioresistant at myeloablative doses of radiation and only poorly immunogenic. Neither 
radiation nor vaccine therapy affords protection.[48] We first engrafted A20 subcutaneously 
to monitor the progression of a single tumor at a known site. The tumors were allowed to 
grow until the average volume reached 150 mm3. Starting at day 10 p.i., a total of 5 doses of 
VHH7-DM1 at 125 µg/injection (5 mg/kg) were administered every other day, with daily 
monitoring of tumor size (Figure 4a). Final sizes of tumors in the VHH7-DM1 treated group 
remained significantly smaller than those in the PBS-treated control [mean: 1479 mm3 
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(controls) v.s. 480 mm3 (VHH7-DM1 treated), p = 0.012, n=3]. Mice treated with VHH7 
alone were no different from the controls (p = 0.99). We next explored the disseminated A20 
model. After i.v injection of A20 cells, treatment started the next day at 125 µg/injection (5 
mg/kg) every other day for a total of 4 injections. Mice were sacrificed on day 27 when 
metastatic foci in the livers of the control group became palpable. We enumerated the liver 
foci for untreated and VHH7/Enh-DM1 treated groups (Figure 4b). The efficacy of VHH7-
DM1 in limiting metastasic spread is encouraging, in that no more than 3 small foci (Φ < 
3mm) were found for the treated group. In untreated animals and in the Enh-DM1 treated 
group, massive liver metastases [liver weight = 4.8 ± 0.87 g (mean ± SD), n = 5, normal 
weight ~1.4 g] were seen, with up to 30 foci. Survival was monitored in a parallel 
experiment (Figure S7). After 4 injections, VHH7-DM1-treated mice showed increased 
median survival of 44 days, compared to 29 days for animals treated with Enh-DM1. No 
nephrotoxicity was observed after 6 injections, as inferred from creatinine levels [0.27 
± 0.06 mg/ml (mean ± SD), n=3, normal range 0~1 mg/ml]. Injection of healthy mice with 
two doses of VHH7-DM1, followed by analysis of splenocytes by FACS analysis 5 days 
later did not show significant differences in MHC-II+ populations [CD19+ (B-cells): 52.1% 
v.s. 51.3%; CD11b+CD11c− (macrophages): 1.7% v.s. 1.6%; CD11b+CD11c+(DCs): 0.4% 
v.s. 0.3%; control v.s. injection; average of two].
In summary, we generated a homogeneous anti-MHC-II nanobody-drug conjugate (VHH7-
DM1) through SrtA-mediated protein conjugation. The conjugate was characterized in vivo 
and in vitro and was efficient in treating an aggressive murine B-cell lymphoma. The 
favorable pharmacokinetics of VHH conjugates outcompete commercial mAbs for 
internalization and clearance providing reduced systemic cytotoxicity and convenient non-
invasive imaging.
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Synthesis and characterization of structurally defined VHH7-DM1 conjugate. a) Preparation 
of VHH7-DM1 conjugate. Conditions: i) DMF, r.t. 2 h; ii) DMF/PBS = 4/1 (v/v), 18 °C, 16 
h; iii. Srt A (pentamutant), 10mM CaCl2, 50 mM Tris, pH = 7.4, 12 °C, 2~4 h; b) LC-MS 
analysis of VHH7-DM1; c) SDS-PAGE analysis of VHH7-DM1 conjugate (15% gel, 
InstantBlue, faster mobility of VHH7-DM1 was due to the cyclic structure of DM1, LC-MS 
profile attached in Fig. S1c).
Fang et al. Page 8














In vitro characterization of VHH7 conjugates. a) Half maximal effective binding of VHH7-
AF647 to murine lymphoma A20 cells. 5×105 cells were incubated with increasing 
concentration of VHH7-AF647 at 4 °C for 1 h, then washed 3 times and analyzed by flow 
cytometry. b) Internalization of commercial antibody anti-I-A/E-AF488 (M5/114.15.2) and 
VHH7-AF647. Equal molar amount of VHH-AF647 and anti-I-A/E-AF488 were premixed 
and added to cells in poly-L-lysine coated imaging chamber at final concentration of 50 nM. 
After 5 min, cells were washed with ice-cold PBS, then fixed and mounted for confocal 
microscopy. c) In vitro cytoxocity of VHH7-DM1 conjugate on MHC-II positive (A20) and 
negative cell lines (Hela) (n=3, bars, means ± SD).
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Non-invasive NIR imaging of A20 lymphoma by VHH7-AF647 conjugate. (color scale: full 
range, minimum to maximum). a) Balb/c with subcutaneous A20 (left, middle) and MHC-II 
KO (right) were injected with 40 µg VHH7-AF647 or irrelevant Enhancer-AF647 conjugate 
as denoted, then imaged on IVIS. Pictures show 5 h p.i. (black dashed circle highlights 
tumor burden); b) Mouse with subcutaneous A20 was dissected 16 h p.i. of VHH7-AF647 to 
show clear tumor targeting; c) Healthy (left) and A20 intravenously inoculated (right, 4 
weeks p.i.) Balb/c were imaged 5 h p.i. of VHH7-AF647; d) Mouse with metastatic A20 was 
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dissected 5 h p.i. of VHH7-AF647 injection to show clear tumor targeting on lung, liver and 
spleen; e) Organs from metastatic and healthy mice (panel c) were imaged in the same view; 
f) Two Balb/c mice with disseminated A20 lymphoma (4 weeks after inoculation) were 
imaged 24 h p.i. of VHH7-AF647; g) Mice from panel f were dissected to show targeting at 
tumor sites. h) Comparable doses (6400 RFU) of fluorescently labeled VHH7-AF647 and α-
I-A/E-AF647 were injected into mice bearing subcutaneous tumors. The tumors were 
removed and analyzed by FACS. Shift in mean fluorescence intensity: 92K(I-A/E) to 135K 
(VHH7).
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In vivo efficiency of VHH7-DM1 conjugate in treating A20 lymphoma. a) VHH7-DM1 
conjugate inhibited tumor growth in a localized model. 9 Balb/c were inoculated with 2.5 × 
106 A20 cells subcutaneously then randomized into 3 groups at day 10 when tumor burdens 
became measurable by caliper. Starting at day 10, samples were given i.v. at dose of 125 µg/
mice (5 mg/kg for 25 g mice) and followed every other day for a total of 5 injections. Tumor 
volume (V) was used to evaluate tumor size using a modified ellipsoid formula: V = 
(width)2 × length / 2 (Bars, means ± SD, n = 3). Experiment end point was defined as when 
the largest single tumor size exceeded 2000 mm3. b) VHH7-DM1 protected mice from 
tumor metastasis in a disseminated model. 15 Balb/c were inoculated with 1.5 × 106 A20 
subcutaneously, then randomized into 3 groups. Injection started at day 2 with a dose of 125 
µg/mice and followed every other day for a total of 4 injections. Mice were sacrificed on day 
27, and the number of metastatic foci on liver was counted (Bars, means ± SD, n = 5).
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